Deutsche Bank AG Buys New Shares in Emergent Biosolutions Inc. $EBS

Key Points

• Deutsche Bank acquired 189,918 shares of Emergent BioSolutions in the second quarter, worth approximately $1.59 million and representing about 0.37% of the company. Institutional investors collectively own 78.4% of EBS.
• Analyst sentiment is mixed: three analysts rate EBS a Buy, one rates it Hold and two rate it Sell. The stock has an average rating of Hold and an average price target of $10.
• EBS opened at $5.92, well below its 52-week high of $14.06. Although the company beat quarterly revenue and earnings expectations, analysts anticipate a full-year loss of $4.61 per share.

Deutsche Bank AG purchased a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 189,918 shares of the biopharmaceutical company's stock, valued at approximately $1,592,000. Deutsche Bank AG owned about 0.37% of Emergent Biosolutions as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of EBS. Bank of New York Mellon Corp bought a new position in Emergent Biosolutions in the second quarter valued at approximately $1,841,000. State of Wyoming bought a new stake in shares of Emergent Biosolutions during the 2nd quarter worth approximately $203,000. One Wealth Advisors LLC bought a new stake in shares of Emergent Biosolutions during the 2nd quarter worth approximately $139,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at approximately $265,000. Finally, Pacer Advisors Inc. acquired a new stake in shares of Emergent Biosolutions in the 1st quarter valued at approximately $3,454,000. 78.40% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings raised shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, August 21st. HC Wainwright lowered their price objective on shares of Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They issued an "underweight" rating on the stock. Finally, Zacks Research upgraded shares of Emergent Biosolutions to a "hold" rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Emergent Biosolutions currently has an average rating of "Hold" and an average price target of $10.00.

Insider Transactions at Emergent Biosolutions

In other news, SVP Paul Anthony Williams sold 3,000 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by company insiders.

Emergent Biosolutions Trading Down 0.3%

EBS stock opened at $5.92 on Friday. The company has a fifty day moving average price of $6.88 and a two-hundred day moving average price of $8.08. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The stock has a market cap of $303.52 million, a price-to-earnings ratio of -1.67 and a beta of 2.35. Emergent Biosolutions Inc. has a one year low of $4.36 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The business had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Equities analysts anticipate that Emergent Biosolutions Inc. will post -4.61 EPS for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source